临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 190786-44-8

Bepotastine Besilate

中文名称:苯磺酸贝托司汀
CAS号:190786-44-8
分子式: C21H25ClN2O3.C6H6O3S 分子量: 547.06
产品形式: Besilate salt
研发状态: Completed
研发用途: Healthy
研究机构: HK inno.N Corporation
研发日期: Dec-12
研发阶段: Phase 1
Bepotastine Besilate (TAU 284) is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7.

CAS: 1903768-17-1

Danicopan (ACH-4471)

CAS号:1903768-17-1
分子式: C26H23BrFN7O3 分子量: 580.41
产品形式: Free base
研发状态: Active not recruiting
研发用途: Geographic Atrophy
研究机构: Alexion Pharmaceuticals Inc.
研发日期: August 23 2021
研发阶段: Phase 2
Danicopan (ACH-4471, ACH-0144471, ACH-CFDIS, ALXN 2040) is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. Danicopan inhibits alternative pathway of complement (APC) activity, and has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

CAS: 1903008-80-9

Lazertinib

中文名称:兰泽替尼
CAS号:1903008-80-9
分子式: C30H34N8O3 分子量: 554.64
产品形式: free base
研发状态: Completed
研发用途: Healthy
研究机构: Janssen Research & Development LLC
研发日期: May 30 2023
研发阶段: Phase 1
Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4.

CAS: 1902123-72-1

GSK2879552 2HCl

CAS号:1902123-72-1
分子式: C23H28N2O2.2HCl 分子量: 437.40
产品形式: dihydrochloride
研发状态: Terminated
研发用途: Myelodysplastic Syndrome; Myelodysplastic Syndromes
研究机构: GlaxoSmithKline; Parexel
研发日期: July 31 2017
研发阶段: Phase 1 : Phase 2
GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1.

CAS: 1898283-02-7

LY 3200882

中文名称:4-[[4-[[1-环丙基-3-(四氢-2H-吡喃-4-基)-1H-吡唑-4-基]氧基]-2-吡啶基]氨基]-alpha,alpha-二甲基-2-吡啶甲醇
CAS号:1898283-02-7
分子式: C24H29N5O3 分子量: 435.52
产品形式: Free Base
研发状态: Unknown status
研发用途: Colorectal Cancer Metastatic
研究机构: The Netherlands Cancer Institute; Vall d''Hebron Institute of Oncology; Agendia; European Organisation for Research and Treatment of Cancer - EORTC; Azienda Ospedaliera Niguarda Cà Granda; Fundación para la Investigación del Hospital Clínico de Valencia; University of Campania Luigi Vanvitelli; University of Turin Italy; Eli Lilly and Company; Catalan Institute of Health; Universitaire Ziekenhuizen KU Leuven
研发日期: Feb-20
研发阶段: Phase 1 : Phase 2
LY 3200882 is a potent, highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). It potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells and in vivo in subcutaneous tumors in a dose dependent fashion.

CAS: 1898207-64-1

DS-1001b (DS 1001)

中文名称:(E)-3-[1-[5-(2-氟丙烷-2-基)-3-(2,4,6-三氯苯基)-1,2-氧唑-4-羰基]-3-甲基咚多-4-基]丙-2-烯酸2-甲基丙烷-2-胺
CAS号:1898207-64-1
分子式: C29H29Cl3FN3O4 分子量: 608.92
产品形式: Free base
研发状态: Active not recruiting
研发用途: WHO Grade II Glioma
研究机构: Daiichi Sankyo Co. Ltd.; Daiichi Sankyo
研发日期: July 8 2020
研发阶段: Phase 2
DS-1001b is an oral selective inhibitor of mutant IDH1 R132X with potential antineoplastic activity and is designed to penetrate the blood-brain barrier.